Efficacy & Safety of Drotrecogin Alfa (Activated) in Adult Patients with Septic Shock

ID Number 08-1303

Principal Investigator(s)
John M Oropello

Department(s) or Division(s)


The purpose of this research study is to examine the safety and effectiveness of the drug Xigris [drotrecogin alfa (activated)] in patients who have been diagnosed with septic shock. Septic shock is a critical condition caused by an infection in which blood pressure falls dangerously low and many organs do not work because of low blood flow.

Contact Information
Rosanna Del Giudice, RN
(212) 241-3149

Recruiting Patients: No